Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
28.69 EUR | -2.17% | +0.05% | -14.64% |
15/05 | Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer | CI |
15/05 | BAYER AG : Barclays remains Neutral | ZD |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.64% | 3.13TCr | |
+35.01% | 71TCr | |
+28.62% | 60TCr | |
-2.60% | 37TCr | |
+20.83% | 33TCr | |
+5.69% | 29TCr | |
+14.74% | 24TCr | |
+9.47% | 21TCr | |
-3.76% | 20TCr | |
+10.77% | 17TCr |
- Stock Market
- Equities
- BAYN Stock
- News Bayer AG
- Bayer to Appeal US Court Decision to Cut 60% Punitive Damages from Weedkiller Cancer Verdict